


Study identifies potential treatment target for prostate cancer resistant to hormone therapy

June 12 2023, by Laurie Fickman



TRAF4 overexpression promotes 22Rv1 and VCaP cell androgen-independent cell growth. (A) MTS cell proliferation assay was performed in TRAF4 overexpressing 22Rv1 and VCaP cells or control cells grown in culture media with and without 1nM androgen (DHT). (B) TRAF4 knockdown reduced 22Rv-1



xenograft (subcutaneously injected) tumor growth (left panel) in castrated mice (n=6). Mice received 2mg/ml doxycycline containing water to induce TRAF4 knockdown starting at the time of cell injection. Middle panel: the tumor weights of control or TRAF4 knockdown tumors. Right panel: Western blot analysis of the protein levels of TRAF4 in shTRAF4 vs. shctrl 22Rv-1 cells. * represents P

Citation: Study identifies potential treatment target for prostate cancer resistant to hormone therapy (2023, June 12) retrieved 12 May 2024 from https://medicalxpress.com/news/2023-06-potential-treatment-prostate-cancer-resistant.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.